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Abstract  
Objectives: A prospective study was conducted to assess the acute and late 
toxicity of hypofractionated whole breast irradiation with a weekly concomitant 
boost for women with early breast cancer (EBC).  
Methods: Women with EBC who underwent breast-conserving surgery were 
eligible. A dose of 40Gy in 15 fractions over 3 weeks was delivered to the whole 
breast with a concomitant weekly boost to the post-operative cavity of 3Gy in 3 
fractions. Toxicity was graded using the RTOG acute toxicity and RTOG/EORTC 
late toxicity scales.  
Results: A total of 67 women were enrolled with a median age of 49 years (range 
31Ð69). Median follow up was 25 months (range 11-34). Acute skin reactions 
included grade (G) 1 (n=47, 70%), G2 (n=10, 13%) and G3 (n=1, 1.5%). Late 
skin toxicity was observed in 13 patients (19%), all of whom experienced G1 
toxicity only. On multivariable analysis, diabetes mellitus was predictive of acute 
skin toxicity (p=0.003), while age less than 50 years (p=0.029) and diabetes 
mellitus (p=0.013) were predictive of late skin toxicity. 
Conclusions: Whole breast irradiation with concomitant weekly boost appears 
feasible and safe. Further investigation is required to fully evaluate this schedule 
as an alternative to conventional whole breast irradiation with a sequential boost.  
Keywords: breast cancer, radiotherapy, tumour bed boost, hypofractionation 
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Manuscript: 
Introduction 
Breast radiotherapy is considered a standard adjuvant treatment for patients with 
early breast cancer (EBC) following breast-conserving surgery (BCS)[1]. 
Adjuvant whole breast radiotherapy has been shown to improve local control 
(LC) and overall survival, with a 70% reduction in recurrence risk[2,3] and a 9-
12% reduction in risk of death[4-6].  
 
Prospective randomized trials have demonstrated that the use of a tumor bed boost 
following whole breast irradiation reduces local recurrence risk, including in 
patients with negative surgical margins[7]. Traditionally, external beam 
radiotherapy consists of two phases: 50Gy delivered to the whole breast in 25 
fractions over 5 weeks (5 fractions per week) followed by 10-16Gy delivered to 
the post-operative cavity in 5-8 fractions over 1-2 weeks[8]. 
 
Over the last few years, there has been renewed interest in hypofractionated 
whole breast irradiation (HF-WBI), defined as a larger daily dose delivered over a 
shorter time. This approach has important practical advantages and biological 
implications. The reduced total treatment time affords convenience for patients 
with decreased resource utilization. Furthermore, large randomized trials with 5- 
to 10-years follow-up have shown equivalence with regards to LC and cosmetic 
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outcome between HF-WBI and conventionally fractionated breast radiotherapy[9-
11]. None of these trials included a simultaneous integrated boost; where boosts 
were included, these were delivered sequentially. In these studies, approximately 
50% of patients received a tumour bed boost using conventional fractionation (2 
Gy/fraction, total dose 10Gy)[10,11]. 
 
In order to intensify treatment, a simultaneous boost dose, concomitant or 
integrated, has been introduced into clinical practice, using 3-D conformal or 
intensity-modulated radiotherapy[12-15]. Preliminary results from previously 
published experiences of concomitant and integrated breast boost radiotherapy 
appear interesting and clinically feasible with acceptable acute 
toxicity[13,15,16,17]. 
 
The primary endpoints of this study were to assess the acute and late toxicity of a 
HF-WBI (3 week) schedule with a concomitant tumour bed boost delivered once 
weekly in women with EBC. Secondary endpoints included LC and overall 
survival. Patient and treatment characteristics predictive of toxicity were also 
investigated. 
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Methods 
Patients 
After institutional approval, this prospective study enrolled patients between 
January 2012 and December 2013. Inclusion criteria were: age  ≥ 18 years, 
histologically proven unilateral EBC, prior conservative surgery (lumpectomy or 
quadrantectomy), pathological stage pT1-pT2, pN0 (AJCC-UICC, 6
th
 edition) and 
negative surgical margins (≥2mm). 
 
Patients with a previous history of contralateral breast irradiation, synchronous 
bilateral breast cancer, positive lymph nodes and/or connective tissue disorders 
were excluded. 
 
Radiotherapy 
 
Timing: Radiotherapy was planned either immediately after conservative surgery 
in patients at low risk of distant failure, or sequentially after adjuvant 
chemotherapy in patients at higher risk of progression. Risk classification was 
based on tumor size, grade, hormonal receptor status, HER-2 receptor status and 
age. 
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Radiotherapy fractionation: Whole breast irradiation consisted of 40Gy delivered 
in 15 fractions, 5 times a week, for 3 weeks. Once a week, immediately after 
whole breast irradiation, a concomitant photon 1Gy boost was delivered to the 
postoperative cavity, thus a total boost dose of 3Gy in 3 weekly fractions was 
delivered. The total treatment duration was 3 weeks and the total nominal dose to 
the lumpectomy area (considering cumulative dose to whole breast and surgical 
bed) was 43Gy.  
 
Radiobiological equivalent dose: The linear-quadratic cell survival model[18] 
was used to calculate the biological equivalent doses received by breast, tumour 
bed and normal tissues using both conventionally fractionated whole breast 
radiotherapy with sequential boost, HF-WBI with weekly concomitant boost and, 
for comparison, HF-WBI without boost, as shown in Table 1. Here, α/β ratios of 
4Gy for breast tumor response, 10Gy for acute responding normal tissues, 1.7Gy 
for late responding normal tissues (fibrosis) and 2.5Gy for vascular damage were 
employed[18].  
  
Volumes of interest and treatment planning: A planning CT scan was performed 
for each patient positioned supine on a "wing-board" with both arms above the 
head. Radiopaque markers were used to delineate the clinically palpable breast 
tissue and visible surgical scars. Three tattoos were made on the thoracic skin to 
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enable accurate repositioning. The scan extended from the larynx to upper 
abdomen, including both lungs. 
  
The whole breast clinical target volume (WB-CTV) included the glandular breast 
tissue from 3-5mm deep to the overlying skin to the surface of the pectoralis 
major and serratus anterior muscles. The whole breast planning target volume 
(WB-PTV) was a 5mm circumferential expansion around the WB-CTV and 
10mm cranio-caudally. 
  
The delineation of the post-operative cavity was guided by surgical clips, seroma 
or other surgical changes considered part of the cavity. The boost CTV was 
generated by adding a 5mm margin around the postoperative cavity, modified 3-
5mm to exclude the skin surface, and extended to the surface of the pectoralis 
muscle and chest wall. The corresponding PTV was created by adding a further 
5mm isotropic margin. For planning and dose evaluation, an evaluation PTV 
(eval-PTV) was defined by trimming the PTV 3-5mm from the skin surface. A 
forward-planned multi-segment tangential IMRT plan was generated, aiming for 
100% coverage of the eval-PTV by the 95% isodose. 
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The heart and ipsilateral lung were considered OAR. The heart was contoured 
from the pulmonary trunk superiorly to its base and included the pericardium. 
Major blood vessels were excluded. The whole  ipsilateral lung was contoured.  
 
Follow-up and toxicity assessment: All patients underwent clinical examination 
before irradiation, weekly during treatment and every two months for the first 
year and every three months thereafter. Surveillance for disease recurrence 
included clinical examination at each time point, and baseline mammography at 
eight months from treatment completion and yearly thereafter. Acute toxicities 
were assessed in the first three months from start of RT and graded according to 
the RTOG acute toxicity scale. Late toxicity was scored ≥6 months from the end 
of treatment using the RTOG/EORTC scale for radiation-related toxicity.  
 
Systemic therapy 
All patients received adjuvant chemotherapy. In total, 43 patients (64.2%) 
received adjuvant chemotherapy followed by radiotherapy and 24 (35.8%) 
received radiotherapy followed by chemotherapy. Chemotherapy consisted of 5-
fluorouracil, epirubicin and cyclophosphamide (FEC).  Adjuvant hormonal 
therapy was indicated for all hormonal receptor-positive patients.  
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Statistical analysis  
Data was analyzed using SPSS version 15 (Statistical Package for Social 
Sciences, IBM, Hampshire, UK). Multivariable logistic regression was performed 
to investigate potential patient and treatment characteristics predictive of acute 
and late skin toxicity. A p<0.05 was considered statistically significant.  
 
Results 
In total, 67 patients with operable invasive EBC were enrolled. Patients and tumor 
characteristics are listed in Table 2. In total, thirty-three patients (49%) were <50 
years old. All patients underwent prior breast conservative surgery with ≥2 mm 
margins and level I/II axillary lymph node dissections. Invasive ductal carcinoma 
was the most common pathological subtype (95.5%). Over one quarter (n=19; 
28.4%) of patients had tumors ≤ 2cm in diameter. Most tumors were histological 
grade 2 (58.2%). Adjuvant chemotherapy was received by 43 patients (64.2%) 
prior to radiotherapy and 24 (35.8%) following radiotherapy. Adjuvant hormonal 
therapy was prescribed in 47 patients after (chemo-)radiotherapy completion. 
  
Median breast volume was 1593cc (range: 1150 Ð 2580cc). Median boost volume 
was 250cc (range: 87 Ð 445cc). In total, six patients had diabetes mellitus. 
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Median follow-up was 25 months (range: 11- 34). All patients completed the 
planned radiotherapy treatment. At the time of last follow-up, all patients were 
alive without evidence of locoregional recurrence or distant metastasis. 
 
Acute toxicity 
At the end of radiotherapy, mild acute reactions (grade 1) were observed in 47 
patients (70.1%). Moderate skin toxicity (grade 2) was experienced by 13.4% of 
patients and only one patient, with diabetes mellitus, experienced a grade 3 
reaction. The remaining 10 patients (14.9%) did not experience acute toxicity. 
The frequency of acute skin reactions is summarized in Table 3. 
 
Factors predictive of acute radiation-induced skin toxicity 
On univariable analysis, only diabetes mellitus was predictive of acute radiation-
induced skin toxicity (p=0.0001). Age, breast volume, boost volume and 
chemotherapy prior to radiotherapy were not statistically significant. 
Multivariable analysis revealed that diabetes mellitus was the only significant 
factor predictive of acute toxicity (p=0.003, Odds ratio (OR) 95% CI: 4.997- 
30.82). 
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Late toxicity 
The frequencies of late skin toxicity are reported in Table 4. Late grade 1 skin 
toxicity was observed in 13 patients (19.4%). There was no late toxicity >grade 1. 
 
Factors predictive of late radiation induced skin toxicity                                                               
Age, breast volume, and diabetes mellitus were significant predictors of late 
toxicity (p=0.015, 0.049, and 0.0001 respectively). The use of chemotherapy prior 
to radiotherapy was non-significant (p=0.079). Multivariable analysis identified 
age <50 years (p=0.029, OR 95% CI =1.010 Ð 1.204) and diabetes mellitus (p= 
0.013, OR 95% CI = 0.000 Ð 0.195) as predictive of late radiation-induced skin 
toxicity.  
  
Discussion 
The concept of hypofractionated radiation therapy for breast cancer has been 
addressed in multiple clinical trials given its potential radiobiological advantages 
because of the low α/β ratio of breast cancer. Studies have confirmed that 
adjuvant HF-WBI following breast-conserving surgery offers disease control rates 
and toxicity profiles equivalent to those obtained using conventional 
fractionation[10,11,19,20].  
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This approach could be advantageous for patients at higher risk of local 
recurrence[21], however concerns remain regarding the potential toxicity of 
hypofractionated treatment regimens when also including a boost dose. The 
ASTRO task force developed evidenceÐbased guidelines for whole breast 
hypofractionated radiotherapy in clinical practice in 2011, and did not reach a 
consensus regarding a specific dose-fractionation schedule for the boost dose.  
Indeed, the task force concluded that  ̋on the basis of the published data and the 
collective expert opinion of the panel, boost doses of 10-16Gy in 2-Gy fractions 
or 10Gy in 2.5-Gy fractions were considered acceptable  ̏[22]. 
 
Thus the optimal method of delivering a tumour bed boost with hypofractionated 
irradiation remains unclear. In prospective randomized trials, the use of a tumor 
bed boost following whole breast irradiation reduced the risk of local recurrence, 
including in margins negative patients[22]. Furthermore, an international survey 
demonstrated that 85% and 75% of American and European physicians 
respectively, would deliver a boost, including in the presence of negative 
margins[23]. 
  
Prospective trials of HF-WBI either did not employ a boost or delivered it at the 
discretion of the treating physician or according to departmental policy.  Recent 
phase IÐII trials investigating the role of a concomitant boost in HF-WBI have 
demonstrated the safety and short-term efficacy of this approach. Corvo et al. 
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treated 377 patients with EBC using conformal radiotherapy with a whole breast 
dose of 46Gy in 20 fractions and a concomitant weekly boost of 1.2Gy to the 
lumpectomy site to a total dose of 52Gy. Overall, 85% of patients experienced 
Grade 0-1 acute skin toxicity, 12% experienced Grade 2 and 3% developed grade 
3 acute skin toxicity[24]. Another clinical study involving 65 EBC patients treated 
with HF-WBI (39Gy in 13 fractions in 3 weeks) plus a concomitant weekly boost 
to the lumpectomy cavity (3Gy in 3 fractions) reported that 52% of patients 
experienced grade 0 acute toxicity, 39% experienced grade 1 and 9% developed 
grade 2 acute toxicity. At six months, grade 1 sub-acute toxicity was observed in 
34% of cases and only 6% of patients developed grade 2 toxicity[25]. In addition, 
with a median follow-up of 24 months, Chadha et al, reported no significant 
negative effects from HF-WBI and concomitant boost on breast cosmoses[26].    
 
In this current study, 67 patients with operable EBC were treated using a 
hypofractionated external beam radiotherapy schedule of 40Gy in 15 fractions 
over 3 weeks to whole breast plus a concomitant weekly cavity boost of 3 Gy in 3 
fractions. At the end of treatment, grade 1 skin toxicity was observed in 70.1% of 
patients, 13.4% developed grade 2 skin toxicity and only one patient, with 
diabetes mellitus, experienced grade 3 toxicity. There was no acute skin reaction 
in ten patients (14.9%). These results are similar to that observed in previous 
studies[24,25]. 
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No late toxicity above grade 1 was observed in our study. This result is in 
accordance with other published data[27,28]. Additional studies have, however, 
reported late toxicities greater than grade 1[29]. This may be explained by the use 
of different toxicity assessment scales. In addition, skin fibrosis is commonly 
scored by visual examination and palpation based scales that are potentially 
influenced by physician inter-observer variability. Late skin toxicity was assessed 
in this study although cosmetic outcome was not specifically evaluated. While 
there were no late skin toxicities above grade 1, potentially inferring a minor 
impact of this treatment strategy on cosmesis, this should not be assumed in the 
absence of specific measures of cosmesis, which assess features beyond skin 
changes alone. The authors acknowledge that the lack of data regarding cosmetic 
outcome is a limitation of this current piece of work. 
 
In this study, we analyzed the impact of treatment and patient related factors on 
the development of acute and late radiation toxicity (age, breast volume, previous 
chemotherapy and presence of diabetes mellitus). In the literature, patient age has 
been used as a selection criterion for a breast boost[30]. In this current study age 
<50 years was predictive of late skin toxicity (p=0.029, CI 1.010 Ð 1.204). While 
the rate of late toxicity was low, age should remain a consideration with regards 
to late effects. 
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Breast volume has previously been identified as a relevant factor for skin toxicity. 
In this current study, there was no increase in acute skin toxicity in large breasted 
women (i.e. larger WB-CTV)  (p=0.209), similar to that observed in other trials 
[31,32,33]. In contrast, some authors have reported strong correlations between 
breast volume or size and severity of acute skin toxicity[34,35]. Possible 
explanations for this discrepancy may be the different criteria used to define 
breast volume and, more specifically, a large breast size, as well as the range of 
breast volumes included in different study cohorts. Dorn et al[32] found that 
breast volume was the only patient factor significantly associated with moist 
desquamation on multivariable analysis (p=0.01). Focal moist desquamation was 
experienced by 27.2% of patients with breast volume >2,500ml compared to only 
6.34% of patients with breast volume <2,500ml (p=0.03).  In this current study, 
median breast volume was 1593cc (range 1150 Ð 2580cc), and so breast volumes 
>2500cc were not well represented. 
 
In this current study, the use of adjuvant chemotherapy prior to radiotherapy was 
not predictive of acute and late skin toxicity. In the past, chemotherapy has been 
reported to result in a worsening of long-term fibrosis and cosmetic 
outcome[36,37]. The impact of modern anthracycline-based regimens in patients 
treated with HF-WBI is unknown. 
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Diabetes mellitus was the only variable in this current study identified as a 
statistically significant predictor of acute skin toxicity on univariable (p<0.001) 
and multivariable (p=0.003, OR 95%CI = 5.00-30.82) analyses, similar to what 
has been observed in some other trials[38,39]. In contrast, other groups have 
reported no significant correlation between diabetes mellitus and acute skin 
toxicity[29]. Clearly, the number of patients with diabetes mellitus in our cohort 
(n=6, 9%) was low and not all diabetic patients are at equal risk. Literature review 
demonstrates that patients with type I diabetes may be at greater risk of radiation 
morbidity[39]. Additionally, Ferro et al, observed that patients receiving 
concurrent metformin and radiotherapy experienced an increased frequency of 
treatment breaks and desquamation[40]. The impact of diabetes mellitus, type I or 
II, and its treatments, on radiation-induced toxicity, therefore, requires further 
investigation. 
 
Radiobiological comparisons of conventional and hypofractionated regimens, as 
shown in Table 1, suggest that the hypofractionated schedule employed here 
delivers a lower total dose to the breast and tumour bed and a similar or slightly 
lower dose to the normal late responding tissues. These doses, theoretically, could 
therefore result in lower rates of tumour control, as well as similar levels of, or 
slight reductions in, late toxicities. The clinical evidence to date, however, in 
terms of whole breast dose, suggests, as above, that HF-WBI regimens are 
equivalent in terms of both tumor control and toxicity[10,11,19,20]. Importantly, 
all of our patients had negative surgical margins, and mainly grade 1 or 2 
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tumours, and in this situation, it may be that a lower boost dose can provide 
adequate control, without excessive toxicity. In addition, all patients received 
chemotherapy, which may provide additional protection from relapse. Further 
evaluation, and longer follow-up, of patients treated with the schedule employed 
here, including the concomitant boost, is, however, required to more fully 
determine the safety and efficacy of this approach.  
 
Outcomes from the recently closed to accrual RTOG 1005 phase III trial (40Gy in 
15 fractions to whole breast with concomitant 3.2Gy per fraction boost to the 
tumour bed (total boost dose 48Gy in 15 fractions) vs. 50Gy in 25 fractions with 
sequential 12-14Gy in 2Gy per fraction tumour bed boost) are eagerly awaited, 
and will guide future practice[41]. Similarly, the ongoing phase III IMPORT-
HIGH, IMRT MC-2 and UZB trials also investigate HF-WBI with concomitant 
tumour bed boosts, and will also help determine the optimal way to deliver breast 
and tumour bed radiotherapy[42-44]. 
 
Conclusion 
Hypofractionated whole breast irradiation with concomitant weekly boost appears 
feasible and safe. Further research is required to demonstrate the efficacy of this 
schedule as an alternative option to standard sequential boost techniques. 
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Table 1: Biological comparison between standard adjuvant radiotherapy 
schedule and explored weekly concomitant boost schedule 
Radiotherapy 
schedule 
BED  
tumor control 
(α/β = 4 Gy) 
BED  
acute effect 
(α/β = 10 
Gy) 
BED 
 fibrosis 
(α/β = 1.7 
Gy) 
BED  
vascular damage 
(α/β = 2.5 Gy) 
 WB          BS WB         BS WB         BS WB         BS 
50Gy in 25 fractions 
over 5 weeks, then 
10Gy in 5 fraction 
sequential boost 
 
75             90 
 
60             72 
 
109         131 
 
90           108 
40Gy in 15 fractions 
over 3 weeks with 
concomitant weekly 
3Gy in 3 fraction 
concurrent boost 
 
68             77 
 
51             56 
 
108         123 
 
86            97 
40Gy in 15 fractions 
over 3 weeks without 
boost 
68             68 51             51 108         108 86           86 
 
Abbreviations: BED: biologically equivalent dose; WB: whole breast; BS: tumor 
bed site. 
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Table 2: Patient and tumor characteristics 
Characteristics Total number=67 
n                                        % 
  Median age (range) 49  (31 Ð 69) 
  Diabetes mellitus 6                                      (9%) 
  Histological type 
        Invasive ductal carcinoma 
        Invasive lobular carcinoma 
 
64                                    (95.5%) 
  3                                    (4.5%) 
  Pathological T- stage 
        T1 
        T2 
 
19                                    (28.4%) 
48                                    (71.6%) 
  Pathological N- stage 
        N0  
 
67                                    (100%)  
  Grading 
       G1 
       G2 
       G3 
 
 8                                      (11.9%) 
 39                                    (58.2%) 
 20                                    (29.9%) 
 OestrogenÐProgesterone receptors 
      Positive  
      Negative       
 
  47                                    (70.1%) 
  20                                    (29.9%) 
HER-2 status 
  Negative 
  Positive 
 
57                                      (85.1%) 
10                                      (14.9%) 
Adjuvant  chemotherapy 
   Following radiotherapy 
   Prior to radiotherapy 
67                                      (100%) 
24                                      (35.8%) 
43                                      (64.2%) 
Adjuvant hormonal therapy 
   None      
   Tamoxifen 
   Aromatase inhibitor 
 
20                                      (29.9%) 
33                                      (49.3%) 
14                                      (20.9%) 
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Table 3: Acute toxicity (based on RTOG acute toxicity skin scoring) 
RTOG score Patients  n=67                   % 
Grade 0 
Grade 1 
Grade 2 
Grade 3 
                  10                      14.9% 
                  47                      70.1% 
                   9                        13.4% 
                    1                         1.5% 
                                   
 
Table 4: Late toxicity assessment (based on RTOG/EORTC scale) 
RTOG/EORTC scale  Patients   n=67                    % 
Grade 0 
Grade 1 
                  54                     80.6% 
                  13                      19.4% 
 
 
